Ecoppia Scientific Valuation
Is ECPA-M undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ECPA-M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ECPA-M's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ECPA-M's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ECPA-M?
Other financial metrics that can be useful for relative valuation.
What is ECPA-M's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$40.89m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ECPA-M's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.7x | ||
INTR Inter Gamma Investment | 6.4x | n/a | ₪121.7m |
ORTC O.R.T. Technologies | 13.4x | n/a | ₪62.5m |
ORAD Orad | 0.3x | n/a | ₪56.4m |
UNIT Unitronics (1989) (RG) | 2.5x | n/a | ₪534.0m |
ECPA-M Ecoppia Scientific | 13.5x | n/a | ₪153.4m |
Price-To-Sales vs Peers: ECPA-M is expensive based on its Price-To-Sales Ratio (13.5x) compared to the peer average (5.7x).
Price to Earnings Ratio vs Industry
How does ECPA-M's PE Ratio compare vs other companies in the IL Electronic Industry?
Price-To-Sales vs Industry: ECPA-M is expensive based on its Price-To-Sales Ratio (13.5x) compared to the IL Electronic industry average (3.8x).
Price to Sales Ratio vs Fair Ratio
What is ECPA-M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 13.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ECPA-M's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.